| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Droxidopa (JP18/USAN/INN); Dops (TN); Northera (TN) | ||||||||||
| Product | NORTHERA (Lundbeck Pharmaceuticals LLC) | ||||||||||
| Generic | DROXIDOPA (Ajanta Pharma USA), DROXIDOPA (Ascend Laboratories), DROXIDOPA (Aurobindo Pharma Limited), DROXIDOPA (Bionpharma), DROXIDOPA (CELLTRION USA), DROXIDOPA (Camber Pharmaceuticals), DROXIDOPA (Hikma Pharmaceuticals USA), DROXIDOPA (Lupin Pharmaceuticals), DROXIDOPA (MSN LABORATORIES PRIVATE LIMITED), DROXIDOPA (Novadoz Pharmaceuticals LLC), DROXIDOPA (ScieGen Pharmaceuticals), DROXIDOPA (Slate Run Pharmaceuticals), DROXIDOPA (Sun Pharmaceutical Industries), DROXIDOPA (Tris Pharma), DROXIDOPA (Upsher-Smith Laboratories), DROXIDOPA (Zydus Lifesciences Limited), DROXIDOPA (Zydus Pharmaceuticals (USA)) | ||||||||||
| Formula | C9H11NO5 | ||||||||||
| Exact mass | 213.0637 | ||||||||||
| Mol weight | 213.1873 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Neuropsychiatric agent DG01967 Antiparkinson agent | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antiparkinsonian, Replenisher (noradrenalin) | ||||||||||
| Disease | Parkinson disease [DS:H00057] Multiple system atrophy [DS:H01614] Dopamine beta-hydroxylase deficiency [DS:H01005] | ||||||||||
| Comment | precursor of Norepinephrine [DR:D00076] | ||||||||||
| Target | ADRA1 [HSA:148 147 146] [KO:K04135 K04136 K04137] ADRA2 [HSA:150 151 152] [KO:K04138 K04139 K04140] ADRB [HSA:153 154 155] [KO:K04141 K04142 K04143] | ||||||||||
| Pathway |
| ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] C CARDIOVASCULAR SYSTEM C01 CARDIAC THERAPY C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES C01CA Adrenergic and dopaminergic agents C01CA27 Droxidopa D01277 Droxidopa (JP18/USAN/INN) <JP/US> USP drug classification [BR:br08302] Cardiovascular Agents Alpha-adrenergic Agonists Droxidopa D01277 Droxidopa (JP18/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 116 Antiparkinsonian agents 1169 Others D01277 Droxidopa (JP18/USAN/INN) Drug groups [BR:br08330] Neuropsychiatric agent DG01967 Antiparkinson agent D01277 Droxidopa Drug classes [BR:br08332] Neuropsychiatric agent DG01967 Antiparkinson agent D01277 Droxidopa Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Adrenaline ADRA1 D01277 Droxidopa (JP18/USAN/INN) <JP/US> ADRA2 D01277 Droxidopa (JP18/USAN/INN) <JP/US> ADRB D01277 Droxidopa (JP18/USAN/INN) <JP/US> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D01277 Droxidopa D01277 Droxidopa capsules D01277 Droxidopa fine granules New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D01277 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01277 | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 15 1 C8y C 5.1800 -5.1100 2 C8y C 5.1800 -6.5100 3 C8x C 6.4400 -7.2100 4 C8x C 7.6300 -6.5100 5 C8y C 7.6300 -5.1100 6 C8x C 6.4400 -4.4100 7 O1a O 3.9900 -7.2100 8 C1c C 8.8200 -4.4100 9 C1c C 10.0100 -5.1100 10 C6a C 11.2700 -4.4100 11 O6a O 12.4600 -5.1100 12 O6a O 11.2700 -3.0100 13 O1a O 8.8200 -3.0100 14 N1a N 10.0100 -6.5100 15 O1a O 3.9734 -4.4000 BOND 15 1 1 2 2 2 2 3 1 3 5 8 1 4 3 4 2 5 8 9 1 6 4 5 1 7 9 10 1 8 5 6 2 9 10 11 1 10 6 1 1 11 10 12 2 12 8 13 1 #Up 13 2 7 1 14 9 14 1 #Up 15 1 15 1 |